FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

Last year
Pharma
FDA+

Ab­b­Vie winds down five-year, $350M phil­an­thropy pledge

Last year
Pharma
Marketing

Eu­rope lines up first CRISPR ther­a­py ap­proval

Last year
Pharma
FDA+

Patent thick­et strat­e­gy with ter­mi­nal dis­claimers helps block bi­o­log­ic com­pe­ti­tion, JA­MA let­ter shows

Last year
FDA+
Law

AC Im­mune's Alzheimer's drug heads to PhI­Ib; Cy­to­Dyn HIV drug on full hold; Syn­dax to raise $200M

Last year
News Briefing

To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Last year
Financing
Startups

Re­neo’s PhI­Ib rare dis­ease tri­al fail­ure forces lay­offs, cost cuts — stock plum­mets

Last year
R&D

In­ter­im no more: Ash­ley Ma­g­a­rgee to fill Genen­tech CEO post; Pfiz­er, Mod­er­na make com­mer­cial lead­er­ship ad­just­ments

Last year
Peer Review

Pfiz­er picks up ear­ly-stage ADC can­di­date cleared for sol­id tu­mor tri­als

Last year
Deals

Q&A: JP Mor­gan’s new life sci­ences pri­vate cap­i­tal leader on the bank’s ex­pand­ing am­bi­tions, vet­ting star­tups and ...

Last year
People
Financing

Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

Last year
Financing
Cell/Gene Tx

PhRMA and BIO say Biden’s march-in pro­pos­al cre­ates un­cer­tain­ty in in­dus­try

Last year
Pharma

Re­pub­li­cans pres­sure FDA on for­eign in­spec­tions, threat­en sub­poe­na 

Last year
Pharma
FDA+

FDA ap­proves high-risk neu­rob­las­toma treat­ment for kids and adults

Last year
Pharma
FDA+

Bernie Sanders says he will bring leg­is­la­tion to re­duce pre­scrip­tion drug costs by 50%

Last year
Pharma

Fore! Am­gen to be­come ti­tle spon­sor of Irish Open

Last year
Pharma
Marketing

Sanofi and As­traZeneca to make 230,000 ad­di­tion­al RSV im­mu­niza­tions avail­able, White House says

Last year
Pharma
FDA+

Pub­li­cis Health names new chief ex­ec­u­tive from its agency net­work

Last year
People
Marketing

NightHawk be­comes pure-play CD­MO; Lon­za to make liv­er can­cer drug; BioN­Tech gears up to open first site in Africa

Last year
Manufacturing

'Won­der­ful Christ­mas gift': Fed's sur­prise rate-cut plan springs hope of 2024 biotech mar­ket re­bound

Last year
Financing
Deals

Play­ground rais­es $410M fund, Ar­tis clos­es $200M as bi­ol­o­gy and tech VC con­ver­gence con­tin­ues

Last year
Financing
Startups

Did the FTC have a good rea­son to block the Sanofi-Maze deal?

Last year
Deals
Pharma

Apel­lis ex­pects EU to re­ject eye drug; Ter­ray teams up with Bris­tol My­ers; Van­dria rais­es $20M

Last year
News Briefing

No­vo Nordisk to boost oral GLP-1 man­u­fac­tur­ing via $92.5M buy for Alk­er­mes’ Ire­land fa­cil­i­ty

Last year
Deals
Manufacturing
First page Previous page 229230231232233234235 Next page Last page
A service from the Financial Times